Skip to main content

Table 1 The baseline information of enrolled subjects in the study

From: Urine metabolomics for assessing fertility-sparing treatment efficacy in endometrial cancer: a non-invasive approach using ultra-performance liquid chromatography mass spectrometry

Characteristics

PT (n = 22)

CR(n = 20)

Age (years), median (range)

35 (32–37)

32 (30–34)

BMI (kg/m2), median (range)

28.2 (24.4–30.9)

26.8 (25.4–31.8)

Laboratory examination, median (range)

  

ALT (U/L)

19 (11–38)

17 (8–33)

Cr (µmol/L)

57 (44–74)

62 (33–76)

Glucose (mmol/L)

5.3 (4.6–12.1)

5.1 (4.0–7.0)

TC (mmol/L)

5.2 (3.3–6.6)

5.1 (3.72–6.2)

TG (mmol/L)

1.1 (0.3–2.8)

1.1 (0.4–3.2)

HDL (mmol/L)

1.3 (0.7–3.7)

1.1 (0.8–2.2)

LDL (mmol/L)

3.0 (1.6–4.8)

3.0 (1.6–4.6)

Urine WBC

0-Trace

0-Trace

Urine RBC

0-Trace

0-Trace

Urine protein (g/L)

0

0

Urine glucose (mmol/L)

0

0

CA125 (U/mL)

20.1 (10.5–32.8)

13.7 (5.5–31.3)

Comorbidity (n, %)

  

DM

3 (13.6%)

3 (15.0%)

HP

2 (9.1%)

2 (10%)

PCOS

2 (9.1%)

2 (10%)

  1. Notes: BMI = body mass index, DM = diabetes mellitus, HP = hypertension, PCOS = polycystic ovary syndrome.